Clearmind Medicine (CMND) shares surged more than 84% premarket Tuesday after the company said it has received Institutional Review Board approval from Yale University for the phase 1/2a clinical trial of CMND-100 in alcohol use disorder.
The company said the approval brings it a step closer to starting the US Food and Drug Administration-regulated clinical program and further expands the multi-site trial.
According to Clearmind Medicine, the trial is designed to evaluate CMND-100's ability to reduce alcohol cravings and consumption among individuals with moderate to severe alcohol use disorder.
Price: 2.25, Change: +1.03, Percent Change: +84.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。